SLU-PP-332

$214.00

Quantity

5mg

Purity Grade

99%

Quantity

Typical Dosing Protocols (Research/Compounded Use Only) Dosing Protocols (Research/Typical Dosing Protocols (Research/Compounded Use Only) – SLU-PP-332

Common protocol: 250–500 mcg subcutaneously once to three times daily (most users start at 250 mcg 1–2x/day and titrate up to 500 mcg per dose). Many run it for 4–8 weeks, followed by a 2–4 week break.
Other reported ranges:
- Beginner: 100–250 mcg 1–3x daily
- Standard: 250–500 mcg 2–3x daily
- Higher: Up to 800–1,000 mcg daily (split doses) in some anecdotal reports
- Frequency: Often 1–3 times per day (morning, pre-workout, or split throughout the day)
Reconstitution example (for a typical 5 mg vial): Add 2 mL bacteriostatic water (yielding ~2.5 mg/mL).
- 250 mcg = 0.1 mL (10 units on U-100 insulin syringe)
- 500 mcg = 0.2 mL (20 units)
Administration: Subcutaneous injection (abdomen or thigh), preferably in a fasted state. Some users report oral or sublingual use, but subcutaneous is the most common research route.

Dosing is highly individualized based on goals and response—consult a qualified healthcare provider experienced with peptides for personalized guidance. This is for informational purposes only.)

SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ), with strongest activity at ERRα (EC50 ≈ 98 nM). It was developed by researchers at Saint Louis University (hence "SLU") as an exercise mimetic — a compound that activates many of the same cellular metabolic pathways normally triggered by aerobic/endurance exercise.

It does not increase appetite suppression, food intake changes, or voluntary exercise in animal models. Instead, it directly boosts mitochondrial function, fatty acid oxidation, and energy expenditure at the cellular level.

As of April 2026, SLU-PP-332 is not FDA-approved and remains a research compound only. No human clinical trials have been published yet. It is sold online (often as capsules or raw material) for "research use," but these products are unregulated and not intended for human consumption. Improved orally bioavailable analogs (e.g., SLU-PP-915) are under investigation.

Primary Benefits (All Data from Mouse Studies)

Increased energy expenditure and fat oxidation:
- Activates an "acute aerobic exercise program" in skeletal muscle, leading to higher mitochondrial respiration and fatty acid burning.
- Reduces fat mass accumulation without decreasing food intake.
Weight/fat loss in obesity models:
- In diet-induced obese mice and other metabolic syndrome models, SLU-PP-332 decreased fat mass, improved insulin sensitivity, and alleviated aspects of metabolic syndrome.
- It shifts muscle toward more oxidative (fat-burning) fiber types (e.g., increased type IIa fibers).
Improved exercise endurance:
- Treated mice ran significantly longer and farther on treadmills (up to 70% longer and 45% farther in some studies) even without prior training.
Metabolic health improvements:
- Better glucose handling and insulin sensitivity.
- Potential benefits for conditions linked to poor mitochondrial function (obesity, diabetes, age-related muscle decline).

These effects mimic key adaptations from regular endurance training (increased oxidative capacity, mitochondrial biogenesis via ERR pathways) without the need to exercise more.

Comparison Context (Relative to Previously Discussed Agents)

Vs. Incretin therapies (Semaglutide, Tirzepatide, Retatrutide, Survodutide, Mazdutide, CagriSema): Incretins drive major weight loss (10–28%+) mainly through strong appetite suppression and slowed gastric emptying. SLU-PP-332 does not reduce appetite or food intake — it works downstream by increasing calorie burning and fat oxidation at the mitochondrial level. It could theoretically complement GLP-1/glucagon agents for additional metabolic benefits.
Vs. Metabolic mimetics (MOTS-c, 5-Amino-1MQ): Both are "exercise-like" at the cellular level. MOTS-c and 5-Amino-1MQ target AMPK or NNMT/NAD+ pathways; SLU-PP-332 specifically activates ERR nuclear receptors to reprogram muscle metabolism toward oxidative endurance.
Vs. GH-axis or regenerative peptides (Sermorelin, CJC-1295, BPC-157, TB-500, GHK-Cu): These focus on growth hormone, tissue repair, or skin rejuvenation. SLU-PP-332 has no significant anabolic or healing effects — it is purely metabolic/exercise-mimetic.
Vs. NAD+ precursors: NAD+ supports general cellular energy; SLU-PP-332 more specifically drives endurance-type muscle adaptations.

Key Potential Benefits of SLU-PP-332
Exercise-Mimetic Effects on Endurance and Physical Performance
Activates ERR-dependent gene programs that replicate many adaptations seen with aerobic exercise training, leading to increased oxidative muscle fiber content and enhanced fatigue resistance.
Significantly boosts exercise endurance, with sedentary mice running up to 50% further and 70% longer on treadmill tests after treatment, without any actual exercise intervention.
Improves overall aerobic capacity, including metrics like running time to exhaustion and distance covered, by promoting mitochondrial function and cellular respiration in muscle tissue.
Potent Support for Fat Loss and Reduced Fat Mass Accumulation
Increases resting energy expenditure and shifts fuel utilization toward greater fatty acid oxidation (up to 25% higher in some models), resulting in reduced fat gain and body weight loss.
In obese mouse models, treatment led to approximately 12% body weight reduction over 28 days while gaining 10 times less fat mass compared to controls, independent of changes in food intake or locomotor activity.
Promotes efficient fat metabolism and decreased adiposity, supporting favorable body composition changes even in high-fat diet or metabolic syndrome contexts.
Enhanced Metabolic Health and Glucose Regulation
Improves insulin sensitivity and glucose tolerance, with lower fasting glucose and insulin levels observed in models of obesity and metabolic syndrome.
Enhances metabolic flexibility, allowing better switching between carbohydrate and fat utilization for energy, which supports overall glycemic control and reduced features of metabolic dysfunction.
Contributes to better lipid profiles, including reductions in total cholesterol and triglycerides in treated obese models.
Mitochondrial Biogenesis and Improved Cellular Energy Production
Upregulates mitochondrial function, respiration, and biogenesis in skeletal muscle cells, leading to more efficient oxygen use and energy generation at the cellular level.
Boosts expression of key target genes (such as those involved in oxidative metabolism and PGC-1α-related pathways), mimicking the mitochondrial adaptations typically induced by endurance training.
Supports sustained energy expenditure and cellular vitality, potentially benefiting tissues with high energy demands like muscle, heart, and brain.
Muscle Fiber Remodeling and Oxidative Capacity
Increases the proportion of slow-twitch, fatigue-resistant (oxidative) muscle fibers, enhancing muscle endurance and resilience without requiring physical training.
Promotes skeletal muscle adaptations that improve nutrient partitioning, recovery processes, and overall muscle metabolic efficiency.
Aids in counteracting age- or inactivity-related declines in muscle oxidative capacity, supporting better physical function in preclinical aging or sedentary models.
Broader Cardiometabolic and Potential Longevity Support
Mimics exercise-induced physiologic adaptations that may benefit cardiovascular health, including improved energy metabolism in cardiac tissue and reduced metabolic syndrome features.
Contributes to systemic benefits such as enhanced fatty acid handling and mitochondrial health, with exploratory links in research to protection against obesity-related complications.
Positions as a tool for studying metabolic optimization, with potential implications for healthy aging, vitality, and resilience in models of reduced physical activity or metabolic stress.

SLU-PP-332

Primary Benefits (All Data from Mouse Studies)

Comparison Context (Relative to Previously Discussed Agents)

SLU-PP-332

Key Potential Benefits of SLU-PP-332

Research

HQ

Social